Hughes Grv.The antiphospholipid syndrome: Ten years on. Lancet1993; 342: 341-344.
2.
Blank M., Cohen J., Toder V., Shoenfeld Y.Induction of antiphospholipid syndrome in naive mice with lupus monoclonal and human polyclonal anti-cardiolipin antibodiesProc Natl Acad Sci USA1991; 88: 3069-3073.
3.
Ross R.The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature1993; 362: 801-809.
4.
Shoenfeld Y. , Isenberg DAThe mosaic of autoimmunity. Immunol Today1989; 10: 123-126.
5.
Wick G. et al. Is atherosclerosis an immunologically mediated disease?Immunol Today1995; 16: 27-32.
6.
Libby P., Hansson GKInvolvement of the immune system in human atherogenesis: Current knowledge and unanswered questions. Lab Invest1991; 64: 5-15.
7.
George J., Harats D., Gilburd B., Shoenfeld Y.Emerging cross-regulatory roles of immunity and autoimmunity in atherosclerosis . Immunol Res1996; 15: 315-322.
8.
Tsakraklidesm VG, Blieden IC, Edwards JECoronary atherosclerosis and myocardial infarction associated with systemic lupus erythematosus. Am Heart J1974; 87: 637-641.
9.
Josson H., Nived O., Sturfelt G.Outcome of systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine ( Baltimore ) 1989; 68: 141-150.
10.
Vaarala O. et al. Anticardiolipin antibodies and the risk of myocardial infarction in a prospective cohort of middle aged men. Circulation1995; 91: 23-27.
11.
Del Papa N. et al. Endothelial cells as target for antiphospholipid antibodies. Arthritis Rheum1997; 3: 551-561.
12.
Tonqueze M. et al. Role of β2-glycoprotein I in the antiphospholipid antibody binding to endothelial cells. Lupus1995; 4: 179-185.
13.
Simantov R.Activation of cultured endothelial cells by antiphospholipid antibodies. J Clin Invest1995; 96: 2211-2219.
14.
Witztum JLThe oxidation hypothesis of atherosclerosis. Lancet1994; 344: 793-795.
15.
Hasunuma Y. et al. Involvement of β2 glycoprotein I and anticardiolipin antibodies in oxidatively modified low density lipoprotein uptake by macrophages. Clin Exp Immunol1997 ; 107: 569-573.
16.
Vaarala O.Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet1993; 341: 923-925.
17.
Vaarala O.Affinity purified cardiolipin binding antibodies show heterogeneity in their binding to oxidized low density lipoprotein. Clin Exp Immunol1996; 104: 269-274.
18.
Mizutani H. et al. Monoclonal anticardiolipin autoantibodies established from the (New Zealand White x BXSB)F1 mouse model for antiphospholipid syndrome cross-react with oxidized low-density lipoprotein. Arthritis Rheum1995; 38: 1382-1388.
19.
George J. et al. Oxidized low density lipoprotein (oxLDL) but not LDL aggravates the manifestations of antiphospholipid syndrome (APS). Clin Exp Immunol1997; 108: 227-233.
20.
Matsuura E. et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol1992 ; 148: 3885-3891.
21.
Gharavi AE et al. Induction of antiphospholipid antibodies by immunization with β2 glycoprotein I (apolipoprotein H). J Clin Invest1992; 90: 1105-1109.
22.
George J. et al. Immunologic characterization and functional properties of murine antibodies raised against deleted mutants of human β2-glycoprotein I. Int Immunol1997; (in press).
23.
Blank M. et al. Immunization with anticardiolipin cofactor (beta-2 glycoprotein-I) induces antiphospholipid syndrome in naive mice. J Autoimmunity1994; 7: 441-448.
24.
George J. et al. Induction of early atherosclerosis in LDL receptor deficient mice by immunization with beta2 glycoprotein I. Submitted.
